About Cellesce
Cellesce is a company based in Cardiff (United Kingdom) founded in 2013 was acquired by Molecular Devices in December 2022. The company has 9 employees. Cellesce operates in a competitive market with competitors including Newcells Biotech, InSphero, Pandorum, Vivodyne and NextVivo, among others.
- Headquarter Cardiff, United Kingdom
- Employees 9
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website cellesce.com
- Social LinkedIn X
- Acquired by Molecular Devices (Dec 2022)
- Legal Name Cellesce Limited
- Date of Incorporation 12 Apr, 2013
- Jurisdiction CARDIFF, WALES
- InvestorsGov.uk
& 4 more
- Employee Count9
- Acquired byMolecular Devices
(Dec 2022)
Funding Insights of Cellesce
- Total Rounds 2
- Investors Count 4
All 2 funding rounds of Cellesce with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2018 | – | Seed | – | – | |
| Apr 2017 | – | Seed | – | – |
5 investors in total: 5 institutional.
Investors in Cellesce
Cellesce has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Gov.uk, Development Bank of Wales and Molecular Devices.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provider of equity funding and business & property development loans | 2001 | developmentbank.wales | Wrexham, United Kingdom | |
Sustainable business finance is provided for companies in Wales. | – | financewales.co.uk | Wrexham, United Kingdom | |
Online government services and information are provided to users. | 1707 | gov.uk | London, United Kingdom | |
A UK organization focused on advancing 3Rs in scientific research. | – | nc3rs.org.uk | London, United Kingdom | |
Automated life science research solutions are provided for various assays. | 1983 | moleculardevices.com | Sunnyvale, United States |
Investor details for Cellesce
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cellesce
1 people are tracked at Cellesce (1 in leadership); the tracked headcount is 9.
| Name | Role | Group |
|---|---|---|
Victoria M. | Chief Executive | Leadership |
Complete people profiles for Cellesce
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cellesce
4 dated milestones of Cellesce across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Cellesce is founded.
- Funding First funding round.
- Funding Latest funding round, Seed,.
- Exit Acquired by Molecular Devices.
Competitors of Cellesce
Cellesce operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Newcells Biotech, InSphero, Pandorum, Vivodyne and NextVivo, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| newcellsbiotech.co.uk | 2014 | Newcastle Upon Tyne, United Kingdom | $14.43M | 22 | Induced pluripotent stem cell-derived organoid models are developed for research. | |
| insphero.com | 2009 | Schlieren, Switzerland | $35.02M | – | Cell-based assays and 3D microtissues for drug screening are developed. | |
| pandorum.com | 2011 | Bengaluru, India | $36.82M | 28 | Regenerative medicine and 3D tissues are developed for therapeutic uses. | |
| vivodyne.com | 2021 | Philadelphia, United States | $117.69M | – | Developer of AI-based platform for lab-grown human tissues | |
| nextvivo.bio | 2021 | Palo Alto, United States | $7.9M | 8 | Immune-competent human-derived models are developed for drug discovery applications. | |
| adapsyn.com | 2016 | Hamilton, United States | – | – | Provider of computational tools for bacterial metabolomic and genomic data analysis | |
| parallel.bio | 2020 | Cambridge, United States | $25.43M | 6 | Limited information available | |
| vyantbio.com | 1999 | Cherry Hill, United States | $10.5M | 25 | Developer of drug discovery platform | |
| neucyte.com | 2015 | Sunnyvale, United States | $6.7M | 10 | Tools for neural cell production are developed using reprogramming technology. |
Detailed competitors of Cellesce
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cellesce
Websites that share an audience with Cellesce (cellesce.com).
Websites whose visitors overlap most with Cellesce. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
google.co.uk | google.co.uk | 100% | – | #355 | – |
Latest news on Cellesce
Complete news archive for Cellesce
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Cellesce
10 companies that operate in the same segment as Cellesce (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cellesce
Cellesce was founded in 2013 and raised its 1st funding round 4 years after it was founded.
Cellesce is headquartered in Cardiff, United Kingdom. It is registered at Cardiff, Wales, United Kingdom.
Cellesce has 9 employees.
Cellesce was founded in 2013 and is based in Cardiff, United Kingdom. Operations center on biotechnology, with a focus on scalable expansion of organoids for drug efficacy testing. These 3D structures replicate in vivo environments. The portfolio encompasses colorectal cancer organoids alongside those from other organs, supporting research applications.
Cellesce's top competitors include Newcells Biotech, InSphero and Vivodyne.
Cellesce has 5 investors. Key investors include Gov.uk, Development Bank of Wales, Molecular Devices, Development Bank of Wales, and NC3Rs.
Cellesce operates through Cellesce Limited.
Yes. Cellesce was acquired by Molecular Devices in December 2022.